Stay updated with breaking news from Clinical Program. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Vivoryon Therapeutics N.V. Reports Full Year 2022 Financial Results and Highlights Operational Progress Significantly advanced varoglutamstat EU and U.S. clinical studies, VIVIAD and VIVA-MIND
– First preclinical data presented for the next generation of the UltraCAR-T platform utilizing a mesothelin (MSLN) chimeric antigen receptor (CAR) – – MSLN is...
/PRNewswire/ -- REGENXBIO Inc. (Nasdaq: RGNX) today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation for RGX-202,...
L.A. city and county leaders celebrated the grand opening of Silva Crossing, a supportive housing project in Sylmar that features 56 studio-bedrooms.
- Topline data for pivotal Phase 3 trial evaluating brilaroxazine for the treatment of schizophrenia remains on track for mid-2023 – - Completed...